Boston Scientific Corporation (BSX) : $7.96 million worth of transactions were on upticks in Boston Scientific Corporation (BSX), compared to $6.97 million on downticks. The ratio between the two was 1.14, whereas, the net money flow stood at a healthy $0.99 million on Fridays session. The consistent buying on upticks in the stock accounted for $1.65million worth of trades. The total money flow into the stock stood at $1.65 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.6%. The stock was trading at $24.19, with a drop of $0.15 over the previous days close. The stock recorded 0.9% for the week.
The company Insiders own 1.31% of Boston Scientific Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -8.82% . Institutional Investors own 92.29% of Boston Scientific Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -26.9%.
In a related news,The director officer (President & CEO) of Boston Scientific Corp, Mahoney Michael F sold 44,400 shares at $24.44 on August 1, 2016. The Insider selling transaction had a total value worth of $1,085,136. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Boston Scientific Corporation (NYSE:BSX): stock was range-bound between the intraday low of $24.12 and the intraday high of $24.43 after having opened at $24.4 on Fridays session. The stock finally closed in the red at $24.4, a loss of -0.29%. The stock remained in the red for the whole trading day. The total traded volume was 5,511,491 shares. The stock failed to cross $24.43 in Fridays trading. The stocks closing price on Thursday was $24.33.
Boston Scientific Corporation (BSX) : Traders are bullish on Boston Scientific Corporation (BSX) as it has outperformed the S&P 500 by a wide margin of 0.63% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.7%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.21% in the last 1 week, and is up 0.5% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.